Microdosing: A valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge

Bioanalysis

Volumn 1, Issue 7, 2009, Pages 1293-1305

  Ings, Robert Mj ^a  

^a RMI Pharmacokinetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

BIOAVAILABILITY; CHEMISTRY; DRUG SCREENING; EVALUATION; HUMAN; INSTRUMENTATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; REPRODUCIBILITY; REVIEW; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, LIQUID; DRUG EVALUATION, PRECLINICAL; HUMANS; MASS SPECTROMETRY; MICROCHEMISTRY; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY;

EID: 79952462634     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.09.107     Document Type: Review

References (38)

1. Bertino JS, Greenberg HE, Reed MD. American College of Clinical Pharmacology position statement on the use of micro-dosing in the drug development process. J. Clin. Pharmacol. 47, 418-422 (2007).
2. Bertino JS, Greenberg HE, Reed MD. Response to comments on ACCP position paper on microdosing. J. Clin. Pharmacol. 47, 1597-1598 (2007).
3. Rowland M. Commentary on ACCP position statement on the use of microdosing in the drug development process. J. Clin. Pharmacol. 47, 1595-1596 (2007).
4. Morgan CJ, Friedmann PS, Church MK, Clough GF. Cutaneous microdialysis as a novel means of continuously stimulating eccrine sweat glands in vivo. J. Invest. Dermatol. 126, 1220-1225 (2006).
5. US FDA. Innovation or Stagnation and Opportunities on the Critical Path to New Drug Development. US FDA, Washington, DC, USA (2004).
6. Midgley I, Fitzpatrick K, Taylor LM et al. Pharmacokinetics and metabolism of the prodrug DB289 (2, 5-bis[4-(Nmethoxyamidino) phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/ antifungal drug DB75 (2, 5-bis(4-guanylphenyl)furan dihydrochloride). Drug Met. Dispos. 35, 955-967 (2007).
7. US FDA. Guidance for Industry, Investigators and Reviewers: Exploratory IND Studies. US FDA, Washington, DC, USA (2005).
8. EMEA. Position Paper on Non-Clinical Safety Studies to Support Clinical Trials with a Single Microdose. EMEA Evaluation of Medicines for Human Use CPMP/SWP/2599/02/Rev 1 (2004).
9. Balani SK, Nagaraja NV, Qian MG et al. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry. Drug Met. Disp. 34, 384-388 (2006).
10. Ni J, Ouyang H, Aiello M et al. Microdosing assessment to evaluate pharmacokinetics and drug metabolism in rats using liquid chromatography-tandem mass spectrometry. Pharm. Res. 25, 1572-1582 (2008).
11. McLean MA, Tam CYJ, Baratta M, Holliman CL, Ings RM, Galluppi GR. Accelerating drug development: methodology to support accelerated first-in-man pharmacokinetic studies by use of drug candidate microdosing. Drug Dev. Res. 67, 1-9 (2007).
12. Ings R, Bourdet D. Getting to the right dose: the microdosing approach. Presented at: Cambridge Healthtech Institute's Sixth Annual World Pharmaceutics Congress. Philadelphia, PA, USA 12-13 June 2007.
13. Sandhu P, Vogel JS, Rose MJ et al. Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. Drug Met. Disp. 32, 1254-1259 (2004).
14. Vogel JS. Accelerator mass spectrometry as a bioanalytical tool. Presented at: 6th Symposium of the International Isotope Society, Philadelphia, PA, USA 14-18 September 1997.
15. Vogel JS, Turtletaub KW, Finkel, R, Nelson DE. Accelerator mass spectrometry. Anal. Chem. 67, A353-A359 (1995).
16. Dueker SR, Lin Y, Buchholz BA et al. Long-term kinetic study of b-carotene, using accelerator mass spectrometry in an adult volunteer. J. Lipid Res. 41, 1790-1800 (2000).
17. Lappin G, Simpson M, Shishikura Y, Garner C. High-performance liquid chromatography accelerator mass spectrometry: correcting for losses during analysis by internal standardization. Anal. Biochem. 378, 93-95 (2008).
18. Vogel JS. Accelerator mass spectrometry for quantitative in vivo tracing. Biotechniques 38, S25-S29 (2005).
19. Turteltaub KW, Vogel JS. Bioanalytical application of accelerator mass spectrometry for pharmaceutical research. Curr. Pharm. Res. 6, 991-1007 (2000).
20. Vogel JS, Love AH. Quantitating isotopic molecular labels with accelerator mass spectrometry. Methods Enzymol. 402, 402-422 (2005).
21. Vogel JS. Rapid production of graphite without contamination for biomedical AMS. Radiocarbon 34, 344-350 (1992).
22. Ognibene TJ, Bench G, Vogel JS, Peaslee GF, Murov S. A high-throughput method for conversion of CO2 obtained from biochemical samples to graphite in septa-sealed vials for quantification of 14C via accelerator mass spectrometry. Anal. Chem. 75, 2192-2196 (2003).
23. Buchholz BA, Freeman SPHT, Haak KW, Vogel JS. Tips and traps in the 14C bio-AMS preparation laboratory. Nucl. Instru. Methods Physics Res. B 172, 404-408 (2000).
24. Lappin G, Kuhnz W, Jochemsen R et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin. Pharmacol. Ther. 80, 203-215 (2006).
25. Stevens LA, Evans P, Shen Z et al. Microdose and microtracer intravenous pharmacokinetics of RDEA806 in healthy subjects. Presented at: The Amercian Society for Clinical Pharmacology and Therapeutics Annual Meeting. National Harbor, MD, USA, 18-21 March 2009.
26. Rowland M. Linear pharmacokinetics demonstrated between a microdose and therapeutic dose of a pgp substrate fexofenadine in humans. Presented at: The Amercian Society for Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL, USA, 2-5 April 2008.
27. Beumer JH, Garner RC, Cohen MB et al. Human mass balance study of a novel anticancer agent ixabepilone using accelerator mass spectrometry. Invest. New Drugs 25(4), 327-334 (2007).
28. Boddy AV, Sludden J, Griffin MJ et al. Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia. Clin. Cancer Res. 13, 4164-4169 (2007).
29. Garner RC, Goris I, Laenen AAE et al. Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study -experience with 14C-labeled (R)-6-[amino94-chlorophenyl) (1-methyl-1H-imidazol-5-yl)methyl]-4- (3-chlorophenyl)-1-methyl-2(1H)-quinoline (r115777), a farnesyl transferase inhibitor. Drug Met. Disp. 30, 823-830 (2002).
30. Stevens L, Frazer N, Dueker S, Church, A, Gaido M. A microdosing study to assess the oral absorption of 14C-EM-1321 in healthy male subjects. Presented at: The American Association of Pharmaceutical Scientists Annual Meeting and Exposition. San Antonio, TX, USA, 28 Octobver 2006.
31. Sarapa N, Hsyu P-H, Lappin G, Garner RC. The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J. Clin. Pharmacol. 45, 1198-1205 (2005).
32. Hall A, Billington A, Brown SH et al. Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl) methyl]-2-pyridinecarboxylate (GSK269984A) an EP91) receptor antagonist for the treatment of inflammatory pain. Biorg. Med. Chem. Lett. (2009) (In press).
33. Collins JM, Grieshaber CK, Chabner BA. Pharmacologically guided phase I clinical trials based upon preclinical drug development. J. Nat. Cancer Inst. 82, 1321-1326 (1990).
34. Boyd RA, Lalonde RL. Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact? Clin. Pharm. Ther. 81, 24-26 (2007).
35. Walker DK. The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. Br. J. Clin. Pharmacol. 58, 601-608 (2004).
36. Buchan P. Smarter candidate selection -utilizing microdosing in exploratory clinical studies. In:Ernst Schering Research Foundation Workshop, Appropriate Dose Selection -How to Optimize Clinical Drug Development. Venitz J, Sittner W (Eds). Springer, USA, 7-27 (2007).
37. Garner RC, Lappin G. The phase 0 microdosing concept. Brit. J. Clin. Pharmacol. 61, 367-370 (2006).
38. Sparreboom A. Unexplored pharmacokinetic opportunities with microdosing in oncology. Clin. Cancer Res. 13, 4033-4034 (2007).